Search research articles
Contact Us
Filters
Showing results (71-80 of 91) with videos related to
Page
of 10
Sort By:
Biomedicines
|
June 2, 2021
Carotid Atherosclerosis, Ultrasound and Lipoproteins
Arcangelo Iannuzzi, Paolo Rubba, Marco Gentile, et al.
Frontiers in Oncology
|
April 12, 2019
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines
Claudia Fumarola, Nicole Bozza, Riccardo Castelli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 13, 2018
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models
Carminia Maria Della Corte, Vincenza Ciaramella, Claudia Cardone, et al.
International Journal of Molecular Sciences
|
May 13, 2023
Alternative Splicing Changes Promoted by NOVA2 Upregulation in Endothelial Cells and Relevance for Gastric Cancer
Anna Di Matteo, Elisa Belloni, Davide Pradella, et al.
Oncotarget
|
December 2, 2017
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism
Claudia Fumarola, Daniele Cretella, Silvia La Monica, et al.
Oncotarget
|
April 9, 2026
Correction: Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism
Claudia Fumarola, Daniele Cretella, Silvia La Monica, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 24, 2016
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation
Silvia La Monica, Denise Madeddu, Marcello Tiseo, et al.
JTO Clinical and Research Reports
|
February 24, 2022
<i>YES1</i> and <i>MYC</i> Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs
Roberta Minari, Samuel Valentini, Denise Madeddu, et al.
Cancer Research
|
September 23, 2020
FAM46C and FNDC3A Are Multiple Myeloma Tumor Suppressors That Act in Concert to Impair Clearing of Protein Aggregates and Autophagy
Nicola Manfrini, Marilena Mancino, Annarita Miluzio, et al.
Scientific Reports
|
March 19, 2024
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models
Silvia La Monica, Federica Vacondio, Kamal Eltayeb, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 91) with videos related to
Sort By:
Page
of 10
Biomedicines
|
June 2, 2021
Carotid Atherosclerosis, Ultrasound and Lipoproteins
Arcangelo Iannuzzi, Paolo Rubba, Marco Gentile, et al.
Frontiers in Oncology
|
April 12, 2019
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines
Claudia Fumarola, Nicole Bozza, Riccardo Castelli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 13, 2018
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models
Carminia Maria Della Corte, Vincenza Ciaramella, Claudia Cardone, et al.
International Journal of Molecular Sciences
|
May 13, 2023
Alternative Splicing Changes Promoted by NOVA2 Upregulation in Endothelial Cells and Relevance for Gastric Cancer
Anna Di Matteo, Elisa Belloni, Davide Pradella, et al.
Oncotarget
|
December 2, 2017
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism
Claudia Fumarola, Daniele Cretella, Silvia La Monica, et al.
Oncotarget
|
April 9, 2026
Correction: Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism
Claudia Fumarola, Daniele Cretella, Silvia La Monica, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 24, 2016
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation
Silvia La Monica, Denise Madeddu, Marcello Tiseo, et al.
JTO Clinical and Research Reports
|
February 24, 2022
<i>YES1</i> and <i>MYC</i> Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs
Roberta Minari, Samuel Valentini, Denise Madeddu, et al.
Cancer Research
|
September 23, 2020
FAM46C and FNDC3A Are Multiple Myeloma Tumor Suppressors That Act in Concert to Impair Clearing of Protein Aggregates and Autophagy
Nicola Manfrini, Marilena Mancino, Annarita Miluzio, et al.
Scientific Reports
|
March 19, 2024
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models
Silvia La Monica, Federica Vacondio, Kamal Eltayeb, et al.
Page
of 10